Hollow Brook Wealth Management LLC Has $1.68 Million Stake in Pfizer Inc. (NYSE:PFE)

Hollow Brook Wealth Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 28.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,326 shares of the biopharmaceutical company’s stock after acquiring an additional 13,041 shares during the quarter. Hollow Brook Wealth Management LLC’s holdings in Pfizer were worth $1,679,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new position in Pfizer during the third quarter worth about $30,000. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE traded down $0.03 on Tuesday, hitting $25.61. 37,889,007 shares of the company traded hands, compared to its average volume of 41,962,758. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The stock has a 50 day simple moving average of $26.88 and a 200-day simple moving average of $28.26. The company has a market cap of $145.02 billion, a PE ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period last year, the company earned $1.14 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.56%. Pfizer’s payout ratio is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.